1. Hybrid immunity in older adults is associated with reduced SARS-CoV-2 infections following BNT162b2 COVID-19 immunisation
- Author
-
Scott J. C. Pallett, Joseph Heskin, Fergus Keating, Andrea Mazzella, Hannah Taylor, Aatish Patel, Georgia Lamb, Deborah Sturdy, Natalie Eisler, Sarah Denny, Esmita Charani, Paul Randell, Nabeela Mughal, Eleanor Parker, Carolina Rosadas de Oliveira, Michael Rayment, Rachael Jones, Richard Tedder, Myra McClure, Elisabetta Groppelli, Gary W. Davies, Matthew K. O’Shea, and Luke S. P. Moore
- Subjects
Medicine - Abstract
Abstract Background Older adults, particularly in long-term care facilities (LTCF), remain at considerable risk from SARS-CoV-2. Data on the protective effect and mechanisms of hybrid immunity are skewed towards young adults precluding targeted vaccination strategies. Methods A single-centre longitudinal seroprevalence vaccine response study was conducted with 280 LCTF participants (median 82 yrs, IQR 76-88 yrs; 95.4% male). Screening by SARS-CoV-2 polymerase chain reaction with weekly asymptomatic/symptomatic testing (March 2020-October 2021) and serology pre-/post-two-dose Pfizer-BioNTech BNT162b2 vaccination for (i) anti-nucleocapsid, (ii) quantified anti-receptor binding domain (RBD) antibodies at three time-intervals, (iii) pseudovirus neutralisation, and (iv) inhibition by anti-RBD competitive ELISA were conducted. Neutralisation activity: antibody titre relationship was assessed via beta linear-log regression and RBD antibody-binding inhibition: post-vaccine infection relationship by Wilcoxon rank sum test. Results Here we show neutralising antibody titres are 9.2-fold (95% CI 5.8–14.5) higher associated with hybrid immunity (p 100BAU/ml), show inhibition
- Published
- 2023
- Full Text
- View/download PDF